CD8A and colitis: A. muciniphila or amuc_1100 has been shown to alleviate colitis and CAC, reduce CD8+ cytotoxic T lymphocytes (cTls), and the infiltration of macrophages in the colon, and may therefore represent a promising therapeutic target for the treatment of colitis and CRC (Wang et al., 2020).